ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and ...
London, UK – 25 October 2013: ViiV Healthcare today announced the submission of a regulatory application in Europe for its investigational single-tablet regimen (STR) combining dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) for the treatment of …